The volume of investments of pharmaceutical enterprises in the Technopolis Moscow SEZ increased 1.6 times

Residents of the Technopolis Moscow Special Economic Zone (SEZ), which produce innovative medicines, invested over 5.8 billion rubles in the city's economy in the first half of 2026. This is 1.6 times more than in the same period last year. This was announced by Maxim Liksutov, Deputy Mayor of Moscow for Transport and Industry.

"On behalf of Moscow Mayor Sergei Sobyanin, a modern pharmaceutical cluster is being formed in the capital. The SEZ is the center of the industry's development “Technopolis Moscow, which already produces a wide range of innovative medicines to combat cancer, cardiology, endocrine, autoimmune and other diseases. In January-June 2026, 15 resident enterprises invested more than 5.8 billion rubles. Over the entire period of operation, pharmaceutical companies that have localized their facilities in the capital's SEZ have invested 70 billion rubles in the city's economy," Maxim Liksutov said.

A pharmaceutical company specializing in the development of biosimilars and innovative drugs for the treatment of cancer, autoimmune diseases, cardiovascular diseases and diabetes mellitus became the leader in terms of investments in the first half of 2026. The company's portfolio already includes seven drugs, and two more are undergoing clinical trials. The company's investments exceeded 2.5 billion rubles. Another manufacturer that will produce drugs from blood plasma has invested a billion rubles.

More than 900 million rubles were invested by a resident who produces medicines, the line of which includes 100 international nonproprietary names. They are used to treat diseases of the gastrointestinal tract, cardiovascular, endocrine, nervous and respiratory systems, as well as to fight microbes, normalize hematopoiesis and other diseases.

Today, the largest pharmaceutical cluster in Russia is being formed on the territory of the Technopolis Moscow SEZ. Two more high-tech enterprises are currently being built on its sites. They were examined by Moscow Mayor Sergei Sobyanin during a visit to the special economic zone. The Artsellens biotechnological complex will produce drugs based on monoclonal antibodies, RNA and cellular technologies, including unique developments with stem cells. A full production cycle of drugs for the treatment of oncological, hormonal and autoimmune diseases will be organized in the new building of the Velpharm-M plant.

Technopolis Moscow Special Economic Zone celebrates its 20th anniversary in 2026. Over two decades, the project has transformed from a launching pad for innovative projects into a key hub for the domestic industry and a center of attraction for companies that determine Russia's technological sovereignty. Today, the production of more than 240 high-tech enterprises representing such strategic areas as microelectronics, instrumentation, biomedicine, IT and robotics is localized at 10 sites of the Technopolis Moscow SEZ with a total area of 430 hectares.

Moscow is actively developing industrial infrastructure for high-tech enterprises. Thanks to urban solutions, companies are increasing production and launching innovative productions. This contributes to the implementation of the national project "Efficient and Competitive Economy".